Market Cap : 51.38 M | Enterprise Value : 57.75 M | PE Ratio : At Loss | PB Ratio : 1.31 |
---|
NAS:ORGS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ORGS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Orgenesis's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2021 was $-4.81 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2021 was $-17.01 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Orgenesis's annualized ROC % for the quarter that ended in Dec. 2021 was -41.75%. Orgenesis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -107.69%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Orgenesis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -29.45%.
The historical data trend for Orgenesis's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Orgenesis's annualized ROC % for the quarter that ended in Dec. 2021 is calculated as:
ROC % (Q: Dec. 2021 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Sep. 2021 ) | + | Invested Capital (Q: Dec. 2021 )) | / count ) |
= | -18.512 * ( 1 - -0.86% ) | / | ( (42.764 | + | 46.684) | / 2 ) |
= | -18.6712032 | / | 44.724 | |||
= | -41.75 % |
where
Invested Capital | (Q: Sep. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 65.204 | - | 7.523 | - | ( 14.917 | - | max(0, 13.566 | - | 36.341 | + | 14.917 | )) |
= | 42.764 |
Invested Capital | (Q: Dec. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 59.841 | - | 7.684 | - | ( 5.473 | - | max(0, 15.365 | - | 25.758 | + | 5.473 | )) |
= | 46.684 |
Note: The Operating Income data used here is four times the quarterly (Dec. 2021) data.
2. Joel Greenblatt's definition of Return on Capital:
Orgenesis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:
ROC (Joel Greenblatt) % | (Q: Dec. 2021 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Sep. 2021 | Q: Dec. 2021 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -19.24 | / | ( ( (6.828 + max(9.547, 0)) | + | (11.286 + max(8.071, 0)) ) | / | 2 ) |
= | -19.24 | / | ( ( 16.375 | + | 19.357 ) | / | 2 ) |
= | -19.24 | / | 17.866 | ||||
= | -107.69 % |
where Working Capital is:
Working Capital | (Q: Sep. 2021 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (15.95 | + | 0.133 | + | 2.154) | - | (7.523 | + | 1.167 | + | 0) |
= | 9.547 |
Working Capital | (Q: Dec. 2021 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (15.245 | + | 0.118 | + | 1.689) | - | (7.684 | + | 1.297 | + | -1.7763568394003E-15) |
= | 8.071 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Dec. 2021) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Orgenesis's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Dec. 2021 ) |
= | -17.008 | / | 57.746 | |
= | -29.45 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Orgenesis's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Sidransky David | director | JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205 |
Reithinger Neil | officer: CFO, Treasurer and Secretary | 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260 |
Philips Mario | director | C/O ATMI, INC DANBURY CT 06810 |
Ferber Sarah | officer: Chief Scientific Officer | 17B HAHASKALA STREET TEL AVIV L3 67890 |
Yachin Guy | director | 7 ORCHARD WAY N POTOMAC MD 20854 |
Nanda Ashish | director | 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452 |
Bedoret Denis | officer: See Remarks | 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041 |
Universite Libre De Bruxelles | other: less than 10% | AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050 |
Theodorus Ii Sa | other: less than 10% | ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
Theodorus Sca | other: less than 10% | ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
Belenger Olivier | other: less than 10% | DIEWEG, 69 BRUSSELS C9 1070 |
Shvartz Oded | 10 percent owner | 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000 |
Bultot Hugues | director | AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150 |
Buyse Chris Georges Frans | director | BAILLET LATOURLEI 119A BRUSSELS C9 2390 |
Tenne Joseph | officer: CFO Treasurer Secretary | 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511 |
Other Sources
By Seekingalpha 2021-11-06